Edgar Filing: Hourican Kevin

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â Hourican Kevin

2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2018

3. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [CVS]

(Last)

(First)

(Middle)

ONE CVS DRIVE

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
EVP & President, CVS Pharmacy

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

WOONSOCKET,Â RIÂ 02895

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,709	D	Â
Common Stock (restricted)	1,232 ⁽¹⁾	D	Â
Common Stock (restricted)	399 ⁽²⁾	D	Â
Common Stock (restricted)	840 ⁽³⁾	D	Â
Common Stock (restricted)	2,444 ⁽⁴⁾	D	Â
Common Stock (restricted)	2,146 ⁽⁵⁾	D	Â
Common Stock (restricted)	3,523 ⁽⁶⁾	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option	04/01/2014⁽⁷⁾	04/01/2020	Common Stock	4,426	$ 54.53	D	Â
Stock Option	04/01/2015⁽⁸⁾	04/01/2021	Common Stock	9,442	$ 74.29	D	Â
Stock Option	04/01/2016⁽⁹⁾	04/01/2022	Common Stock	17,822	$ 102.26	D	Â
Stock Option	04/01/2017⁽¹⁰⁾	04/01/2023	Common Stock	17,611	$ 104.82	D	Â
Stock Option	04/03/2018⁽¹¹⁾	04/03/2024	Common Stock	30,169	$ 78.05	D	Â
Stock Option	04/01/2019⁽¹²⁾	04/01/2025	Common Stock	87,575	$ 62.21	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Hourican Kevin ONE CVS DRIVE WOONSOCKET,Â RIÂ 02895	Â	Â	Â EVP & President, CVS Pharmacy	Â

Signatures

/s/ Kevin P. Hourican		06/08/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Consists of remaining Restricted Stock Units awarded pursuant to Issuer's 2017 Incentive Compensation Plan and its Performance-Based Restricted Stock Unit Plan. Restrictions lapse in three equal installments, commening 2/28/2019.
(2)	Consists of remaining Restricted Stock Units awarded pursuant to Issuer's Performance-Based Restricted Stock Unit Plan, under its 2010 Incentive Compensation Plan. Restrictions lapse 2/28/2019.
(3)	Consists of remaining Restricted Stock Units awarded pursuant to Issuer's Performance-Based Restricted Stock Unit Plan, under its 2010 Incentive Compensation Plan. Restrictions lapse in two equal installments on 2/28/2019 and 2/28/2020.
(4)	Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 4/1/2019.
(5)	Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 4/1/2020.
(6)	Consists of Restricted Stock Units awarded pursuant to Issuer's 2010 Incentive Compensation Plan. Restrictions lapse 4/3/2021.
(7)	Remaining options became exercisable in four equal annual installments beginning on 4/1/2014.
(8)	Remaining options became exercisable in four equal annual installments beginning on 4/1/2015.
(9)	Option became exercisable in four equal annual installments beginning on 4/1/2016.
(10)	Option became exercisable in four equal annual installments beginning on 4/1/2017.
(11)	Option became exercisable in four equal annual installments beginning on 4/3/2018.
(12)	Option becomes exercisable in four equal annual installments beginning on 4/1/2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.